Roberta Marzi

Roberta Marzi

Auto-generated profile, based on publicly available information

Roberta Marzi

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
TSTyler N. Starr
Tyler N. Starr
NCNadine Czudnochowski
Nadine Czudnochowski
ZLZhuoming Liu
Zhuoming Liu
FZFabrizia Zatta
Fabrizia Zatta
YPYoung-Jun Park
Young-Jun Park
GSGyorgy Snell
Gyorgy Snell

3 September 2021 in Science
Verified
Journal Article
Open access
DPDora Pinto
Dora Pinto
MSMaximilian M. Sauer
Maximilian M. Sauer
NCNadine Czudnochowski
Nadine Czudnochowski
JLJun Siong Low
Jun Siong Low
MTM. Alejandra Tortorici
M. Alejandra Tortorici
DVDavid Veesler
David Veesler
Targeting a range of betacoranaviruses: In the past 20 years, three highly pathogenic β-coronaviruses have crossed from animals to humans, including the most recent: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A spike protein that decorates these viruses has an S1 domain that binds host cell receptors and an S2 domain that fuses the viral and cell membranes to allow cell entry. The S1 domain is the target of many neutralizing antibodies but is more genetically variable than S2, and antibodies can exert selective pressure, leading to resistant variants. Pinto et al . identified five monoclonal antibodies that interact with a helix in the S2 domain. The most broadly neutralizing antibody inhibited all β-coronavirus subgenera and reduced viral burden in hamsters infected with SARS-CoV-2. —VV

19 July 2021 in Nature
Verified
Journal Article
Open access
PDF file
MTM. Alejandra Tortorici
M. Alejandra Tortorici
NCNadine Czudnochowski
Nadine Czudnochowski
TSTyler N. Starr
Tyler N. Starr
RMRoberta Marzi
Roberta Marzi
AWAlexandra C. Walls
Alexandra C. Walls
MPMatteo Samuele Pizzuto
Matteo Samuele Pizzuto
The recent emergence of SARS-CoV-2 variants of concern1,2,3,4,5,6,7,8,9,10 and the recurrent spillovers of coronaviruses11,12 into the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift and that can prevent or treat future zoonotic infections. Here we describe a human monoclonal antibody designated S2X259, which recognizes a highly conserved cryptic epitope of the receptor-binding domain and cross-reacts with spikes from all clades of sarbecovirus. S2X259 broadly neutralizes spike-mediated cell entry of SARS-CoV-2, including variants of concern (B.1.1.7, B.1.351, P.1, and B.1.427/B.1.429), as well as a wide spectrum of human and potentially zoonotic sarbecoviruses through inhibition of angiotensin-converting enzyme 2 (ACE2) binding to the receptor-binding domain. Furthermore, deep-mutational scanning and in vitro escape selection experiments demonstrate that S2X259 possesses an escape profile that is limited to a single substitution, G504D. We show that prophylactic and therapeutic administration of S2X259 protects Syrian hamsters (Mesocricetus auratus) against challenge with the prototypic SARS-CoV-2 and the B.1.351 variant of concern, which suggests that this monoclonal antibody is a promising candidate for the prevention and treatment of emergent variants and zoonotic infections. Our data reveal a key antigenic site that is targeted by broadly neutralizing antibodies and will guide the design of vaccines that are effective against all sarbecoviruses.

30 March 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
LMLaura Marongiu
Laura Marongiu
FMFrancesca Mingozzi
Francesca Mingozzi
CCClara Cigni
Clara Cigni
RMRoberta Marzi
Roberta Marzi
MGMarco Di Gioia
Marco Di Gioia
Francesca GranucciFrancesca Granucci
Francesca Granucci
Inflammatory responses of dendritic cells in vitro and in vivo require IP 4 generated by the kinase ITPKB.